Deca (ANABOLIC)

Deca (ANABOLIC) Uses, Dosage, Side Effects, Food Interaction and all others data.

Deca (ANABOLIC) Phenylpropionate is an injectable anabolic preparation. The pharmacologically active substance is nandrolone. The phenylpropionate ester gives the preparation a duration of action of about one week after injection. Deca (ANABOLIC) is chemically related to the male hormone. Compared to testosterone, it has an enhanced anabolic and a reduced androgenic activity. This has been demonstrated in animal bioassays and explained by receptor binding studies. The low androgenicity of nandrolone is confirmed in clinical use.In the human, Deca (ANABOLIC) Phenylpropionate has a nitrogen saving action. This effect on protein metabolism has been established by metabolic studies and is utilized therapeutically in conditions where a protein deficiency exists such as during chronic debilitating diseases and after major surgery and severe trauma. In these conditions, Deca (ANABOLIC) Phenylpropionate serves as a supportive adjunct to specific therapies and dietary measures. In women with disseminated mammary carcinoma, in selected cases Deca (ANABOLIC) Phenylpropionate has been reported to produce objective regressions for many months. Furthermore, Deca (ANABOLIC) Phenylpropionate has been shown to produce relief of bone pain in patients with osteoporosis. The similarly acting nandrolone ester, nandrolone decanoate, has been shown to increase bone mineral content in these patients. Androgenic effects (e.g. virilisation) are relatively uncommon at the recommended dosages. Deca (ANABOLIC) lacks the C17alpha-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.

Deca (ANABOLIC)
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Deca (ANABOLIC)
Availability	Discontinued
Generic	Nandrolone
Nandrolone Other Names	19-norandrostenolone, 19-nortestosterone, Nandrolona, Nandrolone, Nandrolonum
Related Drugs	ferrous sulfate, Arimidex, Ibrance, Femara, Xeloda, Herceptin, Aranesp, Epogen, epoetin alfa
Type
Formula	C₁₈H₂₆O₂
Weight	Average: 274.3978 Monoisotopic: 274.193280076
Groups	Experimental, Investigational
Therapeutic Class	Anabolic steroid (Androgens), Hormone in bone formation by stimulation
Manufacturer
Available Country	Australia
Last Updated:	September 19, 2023 at 7:00 am

Uses

Deca (ANABOLIC) Phenylpropionate is used-

As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance
For the palliative treatment of selected cases of disseminated mammary carcinoma in women
Osteoporosis.

Deca (ANABOLIC) is also used to associated treatment for these conditions: Osteoporosis (Senile), Osteoporosis caused by glucocorticoid

Dosage

Deca (ANABOLIC) dosage

As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance: Recommended dose is 25-50 mg every week.

For the palliative treatment of selected cases of disseminated mammary carcinoma in women: Recommended dose is 50 mg every week.

Osteoporosis: Recommended dose is 50 mg every week.

For an optimal therapeutic effect it is necessary to administer adequate amounts of vitamins, minerals and protein in a calorie-rich diet. Deca (ANABOLIC) Phenylpropionate should be administered by deep intramuscular injection.

Side Effects

High dosages, prolonged treatment and/or too frequent administration may cause:

Virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice.
Amenorrhoea.
Inhibition of spermatogenesis.
Premature epiphyseal closure.
Fluid retention.

Precaution

If signs of virilisation develop, discontinuation of the treatment should be considered, Preferably in consultation with the patient.

It is recommended to monitor patients with any of the following conditions:

latent or overt cardiac failure, renal dysfunction, hypertension or migraine (or a history of these conditions), since anabolic steroids may occasioally induce fluid retention:
incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure;
skeletal metastases of breast carcinoma. In these patients
hypercalcaemia may develop both spontaneously and as a result of anabolic steroid therapy. The later can be indicative of a positive tumour response to the hormonal treatment. Nevertheless, the hypercalcaemia should first be treated appropriately and after restoration of normal calcium levels hormone therapy can be resumed;
liver dysfunction.

The use of anabolic steroids to enhance athletic ability may carry severe risks to the user's health and should be discouraged.

Interaction

Anabolic steroids may improve glucose tolerance and decrease the need for insulin or other antidiabetic medicines in diabetics.

Deca (ANABOLIC) Cholesterol interaction

[Major] Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.

These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.

Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.

Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.

Deca (ANABOLIC) Drug Interaction

Moderate: thyroid desiccatedUnknown: amphetamine / dextroamphetamine, zolpidem, anastrozole, aspirin, tadalafil, testosterone, chorionic gonadotropin , sodium iodide, arginine, acetaminophen, quetiapine, valacyclovir, cyanocobalamin, pyridoxine, cholecalciferol, phytonadione, bupropion, alprazolam, zinc sulfate

Deca (ANABOLIC) Disease Interaction

Major: carcinoma (male), fluid retention, hypercalcemia in breast cancer, hyperlipoproteinemia, liver disease, polycythemia, suppression of clotting factorsModerate: diabetes, hypercalcemiaMinor: thyroid function tests

Pregnancy & Breastfeeding use

This medicine is contraindicated during pregnancy because of possible masculinization of the foetus. There are insufficient data on the use of this medicine during breast-feeding to assess potential harm to the infant or a possible influence on milk production.

Contraindication

Contraindicated in Pregnancy, Known or suspected carcinoma of the prostate or breast in the male.

Acute Overdose

The acute toxicity of Deca (ANABOLIC) Phenylpropionate in animals is very low. There are no reports of acute overdosage with Deca (ANABOLIC) Phenylpropionate in the human